Research progress of statins on immune regulation of multiple sclerosis and experimental allergic encephalomyelitis

Main Article Content

Dongsheng Xu
Manxia Wang

Keywords

Central nervous system, experimental autoimmune encephalomyelitis, immune regulation, multiple sclerosis, statins

Abstract

Objective: The aim of this study is to summarize studies on statins used to treat multiple sclerosis (MS) and experimental allergic encephalomyelitis (EAE) and its underlying mechanisms.


Methods: We searched some representing databases. Some studies were included if the effects of statins were tested on MS and EAE. The methodological quality was evaluated by the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies checklist.


Results: Studies have confirmed that statins have immunomodulatory, neuroprotective and anti-inflammatory effects, and can be used in combination with immunomodulators of different mechanisms to treat MS and EAE. Statins have been shown to improve the following symptoms MS, reduce the number of attacks and the number of lesions, through immunomodulatory, neuroprotective and anti-inflammatory effects, and has a good safety profile.


Conclusions: In short, statins represent an attractive new measure for treating MS. Some studies indicate that in addition to immunomodulatory effects, statins may have neuroprotective and neuro-repairing effects. The combination of statins with other immunosuppressive drugs has also produced encouraging results. This can be broadly prospects prospected to treat MS and EAE. It is hoped that in the near future, a combination of statins with less adverse reactions and high efficacy combined with other immunomodulators will bring exact results to patients with MS.

Abstract 118 | PDF Downloads 127 HTML Downloads 5 XML Downloads 1

References

1. Habek M, Adamec I, Barun B, Crnošija L, Gabelić T, Krbot Skorić M. Clinical neurophysiology of multiple sclerosis. multiple sclerosis: Bench to Bedside. Adv Exp Med. 2017:129–39. 10.1007/978-3-319-47861-6_8

2. Bjelobaba I, Begovic-Kupresanin V, Pekovic S, Lavrnja I. Animal models of multiple sclerosis: focus on experimental autoimmune encephalomyelitis. Journal of neuroscience research. 2018;96(6):1021–42. 10.1002/jnr.24224

3. Herrmann MM, Barth S, Greve B, Schumann KM, Bartels A, Weissert R. Identification of gene expression patterns crucially involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Dis Model Mech. 2016;9(10):1211–20. 10.1242/dmm.025536

4. Jones AP, Kermode AG, Lucas RM, Carroll WM, Nolan D, Hart P. Circulating immune cells in multiple sclerosis. Clin Exp Immunol. 2017;187(2):193–203. 10.1111/cei.12878

5. Lassmann H. Multiple sclerosis pathology. Cold Spring Harb Persp Med. 2018;8(3):a028936. 10.1101/cshperspect.a028936

6. Stephenson J, Nutma E, van der Valk P, Amor S. Inflammation in CNS neurodegenerative diseases. Immunology. 2018;154(2): 204–19. 10.1111/imm.12922

7. Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420(6911):78–84. 10.1038/nature01158

8. Chen Z, Yang D, Peng X, Lin J, Su Z, Li J, et al. Beneficial effect of atorvastatin-modified dendritic cells pulsed with myelin oligodendrocyte glycoprotein autoantigen on experimental auto-immune encephalomyelitis. Neuroreport. 2018;29(4):317-27. 10.1097/WNR.0000000000000962

9. Singh I, Samuvel DJ, Choi S, Saxena N, Singh AK, Won J. Combination therapy of lovastatin and AMP-activated protein kinase activator improves mitochondrial and peroxisomal functions and clinical disease in experimental autoimmune encephalomyelitis model. Immunology. 2018;154(3):434–51. 10.1111/imm.12893

10. Nath N, Giri S, Prasad R, Singh AK, Singh I. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol. 2004;172(2):1273–86. 10.4049/jimmunol.172.2.1273

11. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, MarkovicPlese S, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004;363(9421):1607–8. 10.1016/S0140-6736(04)16205-3

12. Greenwood J, Walters CE, Pryce G, Kanuga N, Bemud E, Baker D, et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 2003;17(8):1-6. 10.1096/fj.02-1014fje

13. Maillart E. Treatment of progressive multiple sclerosis: Challenges and promising perspectives. Rev Neurol 2018;174(6):441–8. 10.1016/j.neurol.2018.01.370

14. Ciotti JR, Cross AH. Disease-modifying treatment in progressive multiple sclerosis. Curr Treat Options Neurol. 2018;20(5): 1–26. 10.1007/s11940-018-0496-3

15. Baldassari LE, Fox RJ. Therapeutic advances and challenges in the treatment of progressive multiple sclerosis. Drugs. 2018;78(15): 1549–66. 10.1007/s40265-018-0984-5%

16. Limagne E, Lançon A, Delmas D, Cherkaoui-Malki M, Latruffe N. Resveratrol interferes with IL1-β-induced pro-inflammatory para crine interaction between primary chondrocytes and macrophages. Nutrients. 2016;8(5):280. 10.3390/nu8050280

17. Luo G, Li Z, Wang Y, Wang H, Zhang Z, Chen W, et al. Resveratrol protects against titanium particle-induced aseptic loosening through reduction of oxidative stress and inactivation of NF-κB. Inflammation. 2016;39(2):775–85. 10.1007/s10753-016-0306-6

18. Maepa M, Razwinani M, Motaung S. Effects of resveratrol on collagen type II protein in the superficial and middle zone chondrocytes of porcine articular cartilage. J Ethnopharmacol. 2016;178:25–33. 10.1016/j.jep.2015.11.047

19. Dunn SE, Youssef S, Goldstein MJ, Prod’homme T, Weber MS, Zamvil SS, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of auto-immunity by atorvastatin. J Exp Med. 2006;203(2):401–12. 10.1084/jem.20051129

20. Deng Y, Wang Z, Chang C, Lu L, Lau CS, Lu Q. Th9 cells and IL-9 in autoimmune disorders: Pathogenesis and therapeutic potentials. Hum Immunol. 2017;78(2):120–8. 10.1016/j.humimm.2016.12.010

21. Noori-Zadeh A, Mesbah-Namin SA, Bistoon-Beigloo S, Bakhtiyari S, Abbaszadeh H-A, Darabi S, et al. Regulatory T cell number in multiple sclerosis patients: A meta-analysis. Mult Scler Relat Disord. 2016;5:73–6. 10.1016/j.msard.2015.11.004

22. Wang H, Zhang H, Huang B, Miao G, Yan X, Gao G, et al. Mesenchymal stem cells reverse high-fat diet-induced non-alcoholic fatty liver disease through suppression of CD4+ T lymphocytes in mice. Mol Med Rep. 2018;17(3):3769–74. 10.3892/mmr.2017.8326

23. Gonçalves RSG, Pereira MC, Dantas AT, Almeida ARd, Marques CDL, Rego MJ, et al. IL-17 and related cytokines involved in systemic sclerosis: perspectives. Autoimmunity. 2018;51(1):1–9. 10.1080/08916934.2017.1416467

24. Melnikov M, Belousova O, Murugin V, Pashenkov M, Boyko A. The role of dopamine in modulation of Th-17 immune response in multiple sclerosis. J Neuroimmunol. 2016;292:97–101. 10.1016/j.jneuroim.2016.01.020

25. Brahmachari S, Pahan K. Myelin basic protein priming reduces the expression of Foxp3 in T cells via nitric oxide. J Immunol. 2010;184(4):1799–809. 10.4049/jimmunol.0804394

26. Kaskow BJ, Baecher-Allan C. Effector T cells in multiple sclerosis. Cold Spring Harb Persp Med. 2018;8(4):a029025. 10.1101/cshperspect.a029025

27. Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier B, Niederwieser G, Hartung H, et al. Statins as immunomodulators: comparison with interferon-β1b in MS. Neurology. 2002;59(7):990–7. 10.1212/WNL.59.7.990

28. Sonar SA, Lal G. Blood-brain barrier and its function during inflammation and autoimmunity. J Leukoc Biol. 2018;103(5):839–53. 10.1002/JLB.1RU1117-428R

29. Ortiz GG, Pacheco-Moisés FP, Macías-Islas MÁ, FloresAlvarado LJ, Mireles-Ramírez MA, González-Renovato ED, et al. Role of the blood-brain barrier in multiple sclerosis. Arch Med Res. 2014;45(8):687–97. 10.1016/j.arcmed.2014.11.013

30. Spencer JI, Bell JS, DeLuca GC. Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier. Journal of Neurology, Neurosurg Psychiatry. 2018;89(1):42–52. 10.1136/jnnp-2017-316011

31. Prajeeth CK, Kronisch J, Khorooshi R, Knier B, Toft-Hansen H, Gudi V, et al. Effectors of Th1 and Th17 cells act on astrocytes and augment their neuroinflammatory properties. J Neuroinflamm. 2017;14(1):1–14. 10.1186/s12974-017-0978-3

32. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7(6):687–92. 10.1038/89058

33. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001;2(7):502–11. 10.1038/35081571

34. Hossain DM, Panda AK, Chakrabarty S, Bhattacharjee P, Kajal K, Mohanty S, et al. MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu. Immunology. 2015;144(4):561–73. 10.1111/imm.12397

35. Letellier E, Haan S. SOCS2: physiological and pathological functions. Front Biosci. 2016;8:189–204. 10.2741/e760

36. Li Y, Chu N, Rostami A, Zhang G-X. Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo. J Immunol. 2006;177(3):1679–88. 10.4049/jimmunol.177.3.1679

37. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008;180(10):6988–96. 10.4049/jimmunol.180.10.6988

38. Sena A, Pedrosa R, Morais MG. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol. 2003;250(6):754–5. 10.1007/s00415-003-1070-8

39. Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler J. 2010;16(7):848–54. 10.1177/1352458510369147

40. Peng X, Jin J, Giri S, Montes M, Sujkowski D, Tang Y, et al. Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. J Neuroimmunol. 2006;178(1–2): 130-9. 10.1016/j.jneuroim.2006.06.005

41. Sarabi ZS, Saeidi MG, Khodashahi M, Rezaie AE, Hashemzadeh K, Khodashahi R, et al. Evaluation of the anti-inflammatory effects of atorvastatin on patients with rheumatoid arthritis: a randomized clinical trial. Electronic Physician. 2016;8(8):2700. 10.19082/2700

42. Li G-m, Zhao J, Li B, Zhang X-f, Ma J-x, Ma X-l, et al. The anti-inflammatory effects of statins on patients with rheumatoid arthritis: a systemic review and meta-analysis of 15 randomized controlled trials. Autoimmun Rev. 2018;17(3):215–25. 10.1016/j.autrev.2017.10.013

43. Castejon R, Castañeda A, Sollet A, Mellor-Pita S, Tutor-Ureta P, Jimenez-Ortiz C, et al. Short-term atorvastatin therapy improves arterial stiffness of middle-aged systemic lupus erythematosus patients with pathological pulse wave velocity. Lupus. 2017;26(4): 355–64. 10.1177/0961203316662719

44. Jorge AM, Lu N, Keller SF, Rai SK, Zhang Y, Choi HK. The effect of statin use on mortality in systemic autoimmune rheumatic diseases. J Rheumatol. 2018;45(12):1689–95. 10.3899/jrheum.171389

45. Carroll JA, Race B, Phillips K, Striebel JF, Chesebro B. Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice. The J Gen Virol. 2017;98(8): 2190. 10.1099/jgv.0.000876

46. Paul F, Waiczies S, Wuerfel J, Bellmann-Strobl J, Dörr J, Waiczies H, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One. 2008;3(4):e1928. 10.1371/journal.pone.0001928

47. Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler J. 2010;16(4):450–4. 10.1177/1352458509358909

48. Li X-l, Zhang Z-c, Zhang B, Jiang H, Yu C-m, Zhang W-j, et al. Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse. Int Immunopharmacol. 2014;23(2):546–9. 10.1016/j.intimp.2014.10.004